Ken Griffin Mereo Biopharma Group PLC Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 83,900 shares of MREO stock, worth $245,827. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,900
Previous 16,700
402.4%
Holding current value
$245,827
Previous $68,000
330.88%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding MREO
# of Institutions
95Shares Held
114MCall Options Held
83.4KPut Options Held
424K-
Janus Henderson Group PLC London, X017.1MShares$50.2 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$44.9 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$28.1 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$25.5 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$25.3 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $366M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...